Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Texas runs out of vital Covid treatment amid dramatic rise in Omicron cases

News from the state comes on the back of warnings about a nationwide monoclonal antibody shortage

Tom Fenton
Tuesday 28 December 2021 09:40 EST
Comments
North Texas COVID-19 testing sites overwhelmed as omicron spreads

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Texas has run out of a vital monoclonal antibody treatment for Covid-19, as the Omicron variant continues to spread at an alarming rate throughout the state.

New data suggests 90 per cent of the state’s Covid cases are the Omicron strain, which has made the need for effective treatment methods even more acute. And yet, as USA Today first reported, as of Monday Texas is now without the sought-after monoclonal antibody sotrovimab.

According to the Texas Department of state health services, it has run out of the treatment in its regional infusion centers in Austin, El Paso, The Woodlands, San Antonio, and Fort Worth. While different monoclonal antibodies haven't proven to be especially effective against Covid, that particular antibody did have a tangible effect on patients – hence its continued usage.

A new shipment of sotrovimab isn’t expected to arrive until January, but with cases currently spiking across the Lone Star state, the timing could hardly be worse. Shortages aren't exclusive to Texas either, as across the US warnings have been issued over vital supplies in the coming weeks and months.

Monoclonal antibodies first garnered national attention as a possible treatment method last year, when former President Donald Trump contracted Covid. As The Hill indicates, the 75-year-old was given Regeneron under a “compassionate use programme” that allowed rare, exceptional circumstances to use the treatment.

(AP)

Since then, however, sotrovimab has emerged as the preeminent antibody treatment for patients who require additional care – although that could be about to change with the FDA now approving several oral medications to combat Covid-19.

Last week the Food and Drug Administration gave emergency use authorisation for two new oral antiviral drugs, the Pfizer Covid-19 pill and the Merck Covid-19 pill. The state expects that those will be available soon but in a limited supply from the federal government. 

Virus Outbreak Treatment Explainer
Virus Outbreak Treatment Explainer (Pfizer)

For the time being, Texans with non-Omicron variants can still receive alternative monoclonal antibody treatments at the many regional infusions centres across the state. In addition, officials are also advising the public to take extra precautions to avoid contracting Covid, primarily by wearing masks, as well as getting a booster shot at the first opportunity to do so.

The Centers for Disease Control and Prevention similarly advise against social gatherings, while recommending that people continue to socially distance and wash their hands whenever possible.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in